RAD 140 comes out as the stronger and more suppressive of the two in RAD 140 vs LGD comparisons outside the trials, and no trial has set them against each other. In the trials, LGD-4033 (ligandrol) raised lean body mass in healthy men while lowering testosterone and high-density lipoprotein (HDL) cholesterol at up to 1 mg daily for three weeks.
The RAD140 trial is a different animal. It enrolled women with metastatic breast cancer, and liver enzymes were raised in most participants; published cases add drug-induced liver injury after exposure to RAD140 outside any trial, while the short, low-dose LGD-4033 trial left those enzymes unchanged.
RAD140, LGD-4033 and ostarine are selective androgen receptor modulators (SARMs), compounds built to bind the androgen receptor, the protein inside cells that mediates androgen action; YK-11 is grouped with the steroidal SARMs in doping-control work, and MK-677 is not a SARM at all. For RAD140 that binding is the RAD 140 mechanism of action, worked out in chemistry and preclinical studies before its first human trial.
This article compares RAD140 with LGD-4033, ostarine, YK-11 and MK-677, one by one, from the trial figures, from the published cases and from the descriptions that lie outside both, and ranks none of them. Each of the five is supplied here for laboratory research with batch and purity data, the buy MK 677 listing among them.
What each compound is and how it acts
RAD140, LGD-4033 and ostarine (MK-2866, enobosarm) are nonsteroidal SARMs, androgen receptor ligands with no steroid backbone; YK-11 (myostine) is a steroidal compound listed alongside them in doping-control analysis; and MK-677 (ibutamoren) falls outside the class as a growth hormone secretagogue, a compound that prompts the release of growth hormone, the pituitary hormone that drives growth and tissue repair.
What each compound is
Compound
Other names
Class
Acts through
RAD140
Testolone, vosilasarm
Nonsteroidal SARM
Androgen receptor
LGD-4033
Ligandrol, VK 5211
Nonsteroidal SARM
Androgen receptor, bound with high affinity and selectivity
Ostarine
MK-2866, enobosarm
Nonsteroidal SARM
Androgen receptor
YK-11
Myostine
Steroidal compound listed with SARMs in doping control
Androgen receptor
MK-677
Ibutamoren
Growth hormone secretagogue, not a SARM
Growth hormone and the IGF-1 pathway
Within the nonsteroidal group the three compounds engage the same receptor, so what differs in the published pharmacology is mainly what was tracked. LGD-4033 binds the androgen receptor with high affinity and selectivity. The SARM RAD140 is orally active, and its first human trial followed receptor engagement through sex hormone-binding globulin (SHBG), the plasma protein that carries sex steroids, and prostate-specific antigen (PSA), a protein secreted by prostate tissue; RAD-140 also showed androgenic activity in two cell bioassays and in an in silico model of the receptor’s ligand-binding domain, where its binding mode differed slightly from those of the two other SARMs tested.
Selectivity of that kind was an aim of the design, not a settled property: the compounds were built to act on skeletal muscle and bone while acting less on prostate tissue, which is why both human trials measured prostate markers.
How MK-677 differs from RAD140
MK-677 differs from RAD140 in the signalling system it engages, so the RAD 140 vs MK-677 comparison sets two mechanisms against each other, one acting through the androgen receptor and the other through growth hormone and the insulin-like growth factor 1 (IGF-1) pathway. The two mechanisms differ in four ways: The same question of what a label declares decides the best MK 677 brand for ibutamoren.
What each acts on: RAD140 binds the androgen receptor, whereas MK-677 acts as a growth hormone secretagogue.
Where the action begins: MK-677’s action begins with hormone release rather than with receptor binding.
The downstream route: MK-677’s downstream effects run through growth hormone and IGF-1.
The pharmacological class: MK-677 belongs to another pharmacological class than RAD140.
MK-677 is still catalogued among SARMs, and whether that MK-677 SARM label holds turns on the mechanism rather than on the catalogue; for the same reason the MK-677 dose cannot be set against SARM doses on one scale. Only one published report names both compounds in a single patient, so its weight is that of a case report rather than of evidence for a shared mechanism.
What the RAD140 and LGD-4033 trials recorded
No trial has compared the two compounds, and their first human trials could hardly have enrolled more different participants. LGD-4033 went to 76 healthy men aged 21 to 50, at 0.1, 0.3 or 1.0 mg daily for 21 days, in a randomised placebo-controlled design that gives one group an inactive comparator; lean body mass rose with the dose, by 1.21 kg over placebo at 1.0 mg, fat mass did not change, leg press rose by 68.3 N at 1.0 mg without reaching significance against placebo, and adverse events were as frequent in the active arms as on placebo. The compound’s developer sponsored the trial.
RAD140’s human record comes from oncology, the compound having entered breast cancer development as vosilasarm. It was administered at 50, 100 or 150 mg once daily to 22 heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, tumours expressing the oestrogen receptor without HER2 amplification, and 100 mg was identified as the maximum tolerated dose, the highest without unacceptable toxicity. Treatment-related adverse events occurred in 77.3% of participants, vomiting, dehydration and decreased appetite and weight each in 27.3%; on efficacy, one partial response was recorded, and the clinical benefit rate at 24 weeks was 18.2%.
Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.
Half-life of RAD140 and LGD-4033 in trial participants
In the breast cancer trial RAD140 had an elimination half-life of 44.7 hours, which supported once-daily administration; in healthy men the elimination half-life of LGD-4033 was 24 to 36 hours. A half-life that long relative to the dosing interval means accumulation, and serum concentrations of LGD-4033 on day 21 were nearly three times those on day 1, in proportion to the dose. The RAD140 figure was derived in women with advanced cancer rather than in healthy volunteers, so the two numbers do not describe comparable physiology.
How much does LGD-4033 lower testosterone compared with RAD140, in figures?
LGD-4033 lowered total testosterone and SHBG in step with the dose at 0.1 to 1.0 mg daily in healthy men, while free testosterone, the unbound fraction available to tissues, and follicle-stimulating hormone (FSH) fell significantly only at 1.0 mg, and luteinising hormone (LH) did not change meaningfully at any dose. The RAD140 trial produced no comparable testosterone figure, because its postmenopausal participants were monitored for receptor engagement instead, SHBG falling in 18 of 18 participants and PSA rising in 16 of 20; RAD-140 LGD-4033 testosterone suppression therefore cannot be stated as two numbers read off one scale.
The variables deserve separate names. Total testosterone covers hormone bound and unbound alike, free testosterone excludes what SHBG and albumin hold, so a fall in SHBG shifts the balance between them, and LH and FSH are the pituitary gonadotrophins that drive testicular steroid and sperm production, which is why LGD-4033 testosterone suppression is judged by their fall as well, read as suppression of the axis rather than of one hormone.
Set directly against each other, the two sets of figures do not line up: one was measured in healthy young men at milligram and sub-milligram doses over three weeks, the other in postmenopausal women with metastatic disease at doses many times higher, so sex, health state and dose range differ all at once. Both trials used compound of known content, as the buy LGD-4033 listing here is documented to be.
How much more suppressive is RAD140 than ostarine, in measured figures?
Accounts outside the published studies describe RAD140 as markedly more suppressive than ostarine, widely described as mild, and that contrast is the whole of RAD-140 vs ostarine testosterone suppression as it is put beyond the trial record; ostarine is the gentler of the pair on the hormonal axis in those accounts, the compound from which less suppression is expected.
Selective androgen receptor modulators comprise compounds that bind as ligands to the androgen receptor and possess tissue-selective activities.
The ordering is not uniform. Beyond the trial data, a few accounts hold a low ostarine amount to be little less suppressive than a low RAD140 amount, and RAD140 is even placed among the less suppressive SARMs when weighed at equal amounts; among the effects described outside the trials, more adverse effects are sometimes attributed to ostarine than to RAD140 even where the RAD140 amount was by far the higher. RAD140 and LGD-4033 are both widely described as far more potent than testosterone on the same scale, and that claim of potency is the usual basis for the claim of suppression.
Liver enzymes and cholesterol in the RAD140 and LGD-4033 trials
The two trials diverge furthest on liver chemistry, and in the RAD140 trial the divergence was graded as well as counted. A raised aspartate aminotransferase (AST) was the most frequent treatment-emergent event of all, ahead of a raised alanine aminotransferase (ALT) and a raised total bilirubin, in the shares of participants the chart below sets out, and some of those AST or ALT elevations reached grade 3 or 4 on the standard toxicity scale, severe or life-threatening, in a share the chart also gives, the same share as the hypophosphataemia recorded in that trial. Neither enzyme changed significantly at any LGD-4033 dose, and PSA, haemoglobin and the QT interval were likewise unchanged.
[Figure 1. Raised AST led the trial’s adverse events. Treatment-emergent liver findings in RAD140’s phase 1 trial: 22 women with advanced breast cancer, 50 to 150 mg daily, no placebo arm. Raised AST was the commonest event of all; 22.7% reached severe grade.]
Lipids ran the other way. LGD-4033 lowered HDL cholesterol in step with the dose, by 19.4 mg/dL at 1.0 mg, and lowered triglycerides as well, and both measures returned towards their pre-treatment values once administration stopped, so the LGD 4033 cholesterol changes in that trial did not persist. The difference in liver findings tracks dose, duration and baseline health as much as the compound: one safety picture comes from heavily pretreated cancer patients at 50 to 150 mg daily, the other from healthy young men at no more than 1 mg over three weeks.
Beside the trials stand single cases, four of RAD 140 liver toxicity, one of the heart and one splenic rupture, none of them with an LGD-4033 counterpart, and they are set out in those articles.
Which is safer, RAD140 or LGD-4033, on liver and cholesterol, with data?
Outside the trial record, RAD140 is described as strongly androgenic, and in comparisons of RAD-140 vs LGD-4033 side effects drawn beyond the trials it is sometimes called the harsher of the two, while in other accounts the LGD-4033 side effects are the heavier of the pair to tolerate, so the ordering reverses from one account to another.
Beyond the published studies the safety question is raised repeatedly and answered from single accounts rather than from any shared measure; in descriptions beyond the trials, a small number of accounts attribute fewer adverse effects to RAD140 than to ostarine, and the question is often widened from the pair to all three compounds at once.
Is LGD better for strength than RAD?
Outside the trials the accounts attribute different things to the two compounds; the first three items below form the commonest division drawn between them:
to LGD-4033, mass rather than strength;
to LGD-4033, more water retained;
to RAD140, strength and drier lean mass;
to RAD140, in some accounts, the place of the stronger of the two outright;
in other accounts outside the published studies, rough equality in potency between the two, with LGD-4033 at higher amounts likened to YK-11.
Elsewhere in the accounts, LGD-4033 is credited with mass and strength together and RAD140 with the second alone, and the strength ordering drawn in RAD 140 vs LGD 4033 accounts shifts with it; beyond the trial data, what separates RAD140 and LGD-4033 is the kind of mass attributed to each, not a ranking that holds from one account to the next.
Ostarine (MK-2866) or RAD 140?
Outside the trials, RAD 140 is described as the stronger compound in the RAD 140 vs ostarine comparison, the second called noticeable but mild and RAD140 likened to a moderate course of testosterone; beyond the trial data, that difference in strength is what separates the two, RAD140 credited with more effect and more adverse effects and ostarine with less of both.
Among the effects described outside the trials, both compounds are called well tolerated, and the ordering is disputed in part: ostarine is sometimes preferred outright, and where many adverse effects are described on ostarine, fewer are described on RAD140. In those accounts what a vial holds is assumed, whereas the ostarine MK-2866 for sale here is documented for every lot.
Whether ostarine adds anything to RAD140 at all is doubted through much of this material, since the two are said to compete for the same androgen receptors and RAD140 is called the stronger. In descriptions beyond the trials, adding ostarine once RAD140 has already suppressed the axis is held to compound the suppression rather than the effect, one compound at a time is preferred in some accounts, and others describe the pair among the RAD140 combinations without a settled verdict on it.
What ostarine dose matches a given RAD140 dose?
In descriptions beyond the trials, the ostarine amount set against a given RAD140 amount is quoted as a multiple of it, because RAD140 is treated as active at a fraction of the ostarine amount; such rough equivalences are offered as orientation rather than as arithmetic, and they rest on the same contrast of a strong compound with a mild one that runs through the rest of this material.
Outside the trial record, a clean conversion between the two compounds is called unattainable. The two are separated there by suppression and by the adverse effects attached to them, not by strength alone, so a single ratio captures none of those dimensions, and where the comparison is made at all it is made in words of more and less rather than in amounts.
Does YK-11 give more strength than RAD140 or LGD-4033?
In accounts outside the published studies, YK-11 and RAD140 are described alike as very strong compounds, and in RAD 140 vs YK11 comparisons no settled ranking emerges against LGD-4033 either: YK-11 is the stronger of the three in part of this material, while elsewhere the three are simply named alongside one another as a single set.
In descriptions beyond the trials, YK-11 and RAD140 are singled out together as the favoured pair in a few accounts, though YK-11 is described far more often on its own than in any settled comparison with the other two; among the effects described outside the trials, the shortness of breath attached to RAD140 raises the recurring question whether YK-11 produces the same effect. The compound is placed alongside RAD140 in these descriptions, with no margin stated between them or against LGD-4033. Those accounts never name the content of the material, which for the YK-11 for sale here is measured for each batch.
Which gives the most muscle with the fewest side effects?
The compound named for the most muscle mass, in descriptions beyond the trials, is usually LGD-4033 or RAD140, with ostarine placed as the milder of the three and credited with less, and the ordering by adverse effects does not simply invert that list: outside the published trials, ostarine is the gentler compound through the greater part of this material, while in at least one account RAD140 was credited with fewer adverse effects than ostarine.
In those accounts no agreed ranking emerges, so the lists of the best SARMs disagree with one another about which compound belongs at the top; the trade-off, more muscle mass against fewer adverse effects, is described rather than placed on a scale, and the three compounds are arranged along it differently from one account to the next.
Doses in the trials against exposure in the case reports
The doses behind the human data sit two orders of magnitude apart: RAD140 was administered at 50, 100 and 150 mg once daily to women with metastatic breast cancer, with 100 mg the maximum tolerated dose, and LGD-4033 at 0.1 to 1.0 mg daily to healthy men over three weeks, and neither schedule was designed to represent what circulates outside a trial.
The published cases record exposure rather than dose, drug-induced liver injury following 5 weeks, three months and 16 weeks of exposure to RAD-140 obtained from consumer products of unverified strength, so the case exposures cannot be read against the trial RAD 140 dose, because the strength behind them is unknown.
Furthermore, these illegal supplements may not contain the declared SARMs at all or may contain incorrect amounts.
A trial dose therefore says nothing about the content of a product sold under the same name. A milligram figure on a label states a declared amount rather than a measured one, and the analytical checks below show how often the declared and the measured part company. For laboratory research the buy RAD 140 UK listing here carries batch and purity data for each lot.
Products labelled testolone, ligandrol or ostarine fail laboratory checks in both directions, too little of the declared compound or none of it, which is what separates legit RAD 140 from the rest.
The rest of the SARMs for sale UK here carry the same batch and purity data.
Return to baseline after LGD-4033
Once administration of LGD-4033 stopped, hormone levels and lipids both returned to baseline, the pre-treatment measurement, within the trial’s five-week follow-up, by day 56; the reversal covered the suppressed testosterone, SHBG, HDL cholesterol and triglyceride values alike, in the men who had received the sub-milligram and milligram doses.
For RAD140 the only recovery data concern liver tissue and are set out in the liver article; nothing comparable exists for its hormonal axis.
RAD140 in cell, rat and mouse studies
In gonadectomised male rats, their gonads surgically removed, RAD140 reduced hippocampal neuron loss in the kainate lesion model, which kills neurons with a systemic excitotoxin, and acted on peripheral tissues while largely sparing prostate tissue.
The cardiac work ran in older animals: mice of 23 months given 5 mg/kg daily for six weeks had an ejection fraction, the share of ventricular volume expelled per beat, 10.4% higher and a stroke volume 9.6 µL higher than controls, with better myocardial strain markers in males than in females. In the cell bioassays androgenic activity was lower in the yeast androgen screen than in the reporter gene assay in prostate carcinoma cells, a difference that bears on whether urinary screens of that kind detect such compounds at all; in cultured rat hippocampal neurons, the cellular side of RAD-140 neuroprotection, the compound matched testosterone against apoptotic insults through MAPK signalling.
What this comparison cannot settle
No trial has set any of these compounds against another, so this RAD 140 vs LGD comparison can rank none of them. The only human RAD140 trial enrolled 22 heavily pretreated women with metastatic breast cancer at doses far above those of the LGD-4033 trial, which in turn ran three weeks in small groups and was sponsored by the compound’s developer; single cases carry the rest of the human record, in one of them the authors call any causal role for the compounds speculative, and even the exposures behind those cases are uncertain, because products sold under these names frequently did not contain what the label declared. One of those cases concerns RAD-140 and the heart.
Seven of the comparisons drawn in this article are known from description alone. No published study among this article’s sources has measured any of them:
how much more suppressive RAD140 is than ostarine;
which ostarine amount matches a RAD140 amount;
whether LGD-4033 or RAD140 gives more strength;
how ostarine and RAD140 differ in strength and mildness;
whether YK-11 gives more strength than RAD140 or LGD-4033;
which of RAD140 and LGD-4033 is safer;
which brings the most muscle mass with the fewest adverse effects.
None of these SARMs has clinical approval, all are prohibited in sport at all times, and doping-control methods cover each of them.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
How does the article classify MK-677 (ibutamoren)?
A growth hormone secretagogue acting via the IGF-1 pathway ✓
A nonsteroidal SARM that binds the androgen receptor
A steroidal SARM grouped with the others in doping control work
An anabolic-androgenic steroid derived from testosterone
MK-677 prompts the release of growth hormone and acts through the IGF-1 pathway, so it is not a SARM despite being sold under that label.
Who were the participants in the only human trial of RAD140?
Healthy young men in a placebo-controlled trial
Postmenopausal women with metastatic breast cancer ✓
Older men with age-related loss of muscle mass
Competitive athletes enrolled through doping control programmes
RAD140 entered human testing as vosilasarm in 22 heavily pretreated women with ER+/HER2- metastatic breast cancer, so its trial figures do not describe healthy people.
What was the most frequent treatment-emergent event in the first RAD140 trial?
A fall in HDL cholesterol and triglycerides
Possible acute myocarditis, inflammation of the heart muscle
A raised aspartate aminotransferase (AST) level ✓
Vomiting, dehydration and decreased appetite
Raised AST was recorded in 59.1% of participants, ahead of raised ALT and bilirubin, while the LGD-4033 trial left both liver enzymes unchanged.
What did the Slovak analysis of 16 SARM supplements bought online find?
Most held the named compound, though at a lower strength
Most also contained an anabolic-androgenic steroid
Most contained a SARM other than the one named on their label
Nearly half did not contain the compound named on the label ✓
A SARM was confirmed in 9 of the 16 products, while in 7 the declared testolone, ostarine or andarine was not reliably identified.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
RAD140 vs testosterone compared on potency, prostate sparing and suppression, from binding assays, rat studies and the one human trial in breast cancer.
RAD 140 vs LGD: trial data, ostarine, YK-11 and MK-677
By Laura Walker, PhD · Reviewed by Elizabeth Hyams
Published · Updated · 19 min read
RAD 140 vs LGD at a glance
RAD 140 comes out as the stronger and more suppressive of the two in RAD 140 vs LGD comparisons outside the trials, and no trial has set them against each other. In the trials, LGD-4033 (ligandrol) raised lean body mass in healthy men while lowering testosterone and high-density lipoprotein (HDL) cholesterol at up to 1 mg daily for three weeks.
The RAD140 trial is a different animal. It enrolled women with metastatic breast cancer, and liver enzymes were raised in most participants; published cases add drug-induced liver injury after exposure to RAD140 outside any trial, while the short, low-dose LGD-4033 trial left those enzymes unchanged.
RAD140, LGD-4033 and ostarine are selective androgen receptor modulators (SARMs), compounds built to bind the androgen receptor, the protein inside cells that mediates androgen action; YK-11 is grouped with the steroidal SARMs in doping-control work, and MK-677 is not a SARM at all. For RAD140 that binding is the RAD 140 mechanism of action, worked out in chemistry and preclinical studies before its first human trial.
This article compares RAD140 with LGD-4033, ostarine, YK-11 and MK-677, one by one, from the trial figures, from the published cases and from the descriptions that lie outside both, and ranks none of them. Each of the five is supplied here for laboratory research with batch and purity data, the buy MK 677 listing among them.
What each compound is and how it acts
RAD140, LGD-4033 and ostarine (MK-2866, enobosarm) are nonsteroidal SARMs, androgen receptor ligands with no steroid backbone; YK-11 (myostine) is a steroidal compound listed alongside them in doping-control analysis; and MK-677 (ibutamoren) falls outside the class as a growth hormone secretagogue, a compound that prompts the release of growth hormone, the pituitary hormone that drives growth and tissue repair.
What each compound is
Within the nonsteroidal group the three compounds engage the same receptor, so what differs in the published pharmacology is mainly what was tracked. LGD-4033 binds the androgen receptor with high affinity and selectivity. The SARM RAD140 is orally active, and its first human trial followed receptor engagement through sex hormone-binding globulin (SHBG), the plasma protein that carries sex steroids, and prostate-specific antigen (PSA), a protein secreted by prostate tissue; RAD-140 also showed androgenic activity in two cell bioassays and in an in silico model of the receptor’s ligand-binding domain, where its binding mode differed slightly from those of the two other SARMs tested.
Selectivity of that kind was an aim of the design, not a settled property: the compounds were built to act on skeletal muscle and bone while acting less on prostate tissue, which is why both human trials measured prostate markers.
How MK-677 differs from RAD140
MK-677 differs from RAD140 in the signalling system it engages, so the RAD 140 vs MK-677 comparison sets two mechanisms against each other, one acting through the androgen receptor and the other through growth hormone and the insulin-like growth factor 1 (IGF-1) pathway. The two mechanisms differ in four ways: The same question of what a label declares decides the best MK 677 brand for ibutamoren.
MK-677 is still catalogued among SARMs, and whether that MK-677 SARM label holds turns on the mechanism rather than on the catalogue; for the same reason the MK-677 dose cannot be set against SARM doses on one scale. Only one published report names both compounds in a single patient, so its weight is that of a case report rather than of evidence for a shared mechanism.
What the RAD140 and LGD-4033 trials recorded
No trial has compared the two compounds, and their first human trials could hardly have enrolled more different participants. LGD-4033 went to 76 healthy men aged 21 to 50, at 0.1, 0.3 or 1.0 mg daily for 21 days, in a randomised placebo-controlled design that gives one group an inactive comparator; lean body mass rose with the dose, by 1.21 kg over placebo at 1.0 mg, fat mass did not change, leg press rose by 68.3 N at 1.0 mg without reaching significance against placebo, and adverse events were as frequent in the active arms as on placebo. The compound’s developer sponsored the trial.
RAD140’s human record comes from oncology, the compound having entered breast cancer development as vosilasarm. It was administered at 50, 100 or 150 mg once daily to 22 heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer, tumours expressing the oestrogen receptor without HER2 amplification, and 100 mg was identified as the maximum tolerated dose, the highest without unacceptable toxicity. Treatment-related adverse events occurred in 77.3% of participants, vomiting, dehydration and decreased appetite and weight each in 27.3%; on efficacy, one partial response was recorded, and the clinical benefit rate at 24 weeks was 18.2%.
Half-life of RAD140 and LGD-4033 in trial participants
In the breast cancer trial RAD140 had an elimination half-life of 44.7 hours, which supported once-daily administration; in healthy men the elimination half-life of LGD-4033 was 24 to 36 hours. A half-life that long relative to the dosing interval means accumulation, and serum concentrations of LGD-4033 on day 21 were nearly three times those on day 1, in proportion to the dose. The RAD140 figure was derived in women with advanced cancer rather than in healthy volunteers, so the two numbers do not describe comparable physiology.
How much does LGD-4033 lower testosterone compared with RAD140, in figures?
LGD-4033 lowered total testosterone and SHBG in step with the dose at 0.1 to 1.0 mg daily in healthy men, while free testosterone, the unbound fraction available to tissues, and follicle-stimulating hormone (FSH) fell significantly only at 1.0 mg, and luteinising hormone (LH) did not change meaningfully at any dose. The RAD140 trial produced no comparable testosterone figure, because its postmenopausal participants were monitored for receptor engagement instead, SHBG falling in 18 of 18 participants and PSA rising in 16 of 20; RAD-140 LGD-4033 testosterone suppression therefore cannot be stated as two numbers read off one scale.
The variables deserve separate names. Total testosterone covers hormone bound and unbound alike, free testosterone excludes what SHBG and albumin hold, so a fall in SHBG shifts the balance between them, and LH and FSH are the pituitary gonadotrophins that drive testicular steroid and sperm production, which is why LGD-4033 testosterone suppression is judged by their fall as well, read as suppression of the axis rather than of one hormone.
Set directly against each other, the two sets of figures do not line up: one was measured in healthy young men at milligram and sub-milligram doses over three weeks, the other in postmenopausal women with metastatic disease at doses many times higher, so sex, health state and dose range differ all at once. Both trials used compound of known content, as the buy LGD-4033 listing here is documented to be.
How much more suppressive is RAD140 than ostarine, in measured figures?
Accounts outside the published studies describe RAD140 as markedly more suppressive than ostarine, widely described as mild, and that contrast is the whole of RAD-140 vs ostarine testosterone suppression as it is put beyond the trial record; ostarine is the gentler of the pair on the hormonal axis in those accounts, the compound from which less suppression is expected.
The ordering is not uniform. Beyond the trial data, a few accounts hold a low ostarine amount to be little less suppressive than a low RAD140 amount, and RAD140 is even placed among the less suppressive SARMs when weighed at equal amounts; among the effects described outside the trials, more adverse effects are sometimes attributed to ostarine than to RAD140 even where the RAD140 amount was by far the higher. RAD140 and LGD-4033 are both widely described as far more potent than testosterone on the same scale, and that claim of potency is the usual basis for the claim of suppression.
Liver enzymes and cholesterol in the RAD140 and LGD-4033 trials
The two trials diverge furthest on liver chemistry, and in the RAD140 trial the divergence was graded as well as counted. A raised aspartate aminotransferase (AST) was the most frequent treatment-emergent event of all, ahead of a raised alanine aminotransferase (ALT) and a raised total bilirubin, in the shares of participants the chart below sets out, and some of those AST or ALT elevations reached grade 3 or 4 on the standard toxicity scale, severe or life-threatening, in a share the chart also gives, the same share as the hypophosphataemia recorded in that trial. Neither enzyme changed significantly at any LGD-4033 dose, and PSA, haemoglobin and the QT interval were likewise unchanged.
Lipids ran the other way. LGD-4033 lowered HDL cholesterol in step with the dose, by 19.4 mg/dL at 1.0 mg, and lowered triglycerides as well, and both measures returned towards their pre-treatment values once administration stopped, so the LGD 4033 cholesterol changes in that trial did not persist. The difference in liver findings tracks dose, duration and baseline health as much as the compound: one safety picture comes from heavily pretreated cancer patients at 50 to 150 mg daily, the other from healthy young men at no more than 1 mg over three weeks.
Beside the trials stand single cases, four of RAD 140 liver toxicity, one of the heart and one splenic rupture, none of them with an LGD-4033 counterpart, and they are set out in those articles.
Which is safer, RAD140 or LGD-4033, on liver and cholesterol, with data?
Outside the trial record, RAD140 is described as strongly androgenic, and in comparisons of RAD-140 vs LGD-4033 side effects drawn beyond the trials it is sometimes called the harsher of the two, while in other accounts the LGD-4033 side effects are the heavier of the pair to tolerate, so the ordering reverses from one account to another.
Beyond the published studies the safety question is raised repeatedly and answered from single accounts rather than from any shared measure; in descriptions beyond the trials, a small number of accounts attribute fewer adverse effects to RAD140 than to ostarine, and the question is often widened from the pair to all three compounds at once.
Is LGD better for strength than RAD?
Outside the trials the accounts attribute different things to the two compounds; the first three items below form the commonest division drawn between them:
Elsewhere in the accounts, LGD-4033 is credited with mass and strength together and RAD140 with the second alone, and the strength ordering drawn in RAD 140 vs LGD 4033 accounts shifts with it; beyond the trial data, what separates RAD140 and LGD-4033 is the kind of mass attributed to each, not a ranking that holds from one account to the next.
Ostarine (MK-2866) or RAD 140?
Outside the trials, RAD 140 is described as the stronger compound in the RAD 140 vs ostarine comparison, the second called noticeable but mild and RAD140 likened to a moderate course of testosterone; beyond the trial data, that difference in strength is what separates the two, RAD140 credited with more effect and more adverse effects and ostarine with less of both.
Among the effects described outside the trials, both compounds are called well tolerated, and the ordering is disputed in part: ostarine is sometimes preferred outright, and where many adverse effects are described on ostarine, fewer are described on RAD140. In those accounts what a vial holds is assumed, whereas the ostarine MK-2866 for sale here is documented for every lot.
Whether ostarine adds anything to RAD140 at all is doubted through much of this material, since the two are said to compete for the same androgen receptors and RAD140 is called the stronger. In descriptions beyond the trials, adding ostarine once RAD140 has already suppressed the axis is held to compound the suppression rather than the effect, one compound at a time is preferred in some accounts, and others describe the pair among the RAD140 combinations without a settled verdict on it.
What ostarine dose matches a given RAD140 dose?
In descriptions beyond the trials, the ostarine amount set against a given RAD140 amount is quoted as a multiple of it, because RAD140 is treated as active at a fraction of the ostarine amount; such rough equivalences are offered as orientation rather than as arithmetic, and they rest on the same contrast of a strong compound with a mild one that runs through the rest of this material.
Outside the trial record, a clean conversion between the two compounds is called unattainable. The two are separated there by suppression and by the adverse effects attached to them, not by strength alone, so a single ratio captures none of those dimensions, and where the comparison is made at all it is made in words of more and less rather than in amounts.
Does YK-11 give more strength than RAD140 or LGD-4033?
In accounts outside the published studies, YK-11 and RAD140 are described alike as very strong compounds, and in RAD 140 vs YK11 comparisons no settled ranking emerges against LGD-4033 either: YK-11 is the stronger of the three in part of this material, while elsewhere the three are simply named alongside one another as a single set.
In descriptions beyond the trials, YK-11 and RAD140 are singled out together as the favoured pair in a few accounts, though YK-11 is described far more often on its own than in any settled comparison with the other two; among the effects described outside the trials, the shortness of breath attached to RAD140 raises the recurring question whether YK-11 produces the same effect. The compound is placed alongside RAD140 in these descriptions, with no margin stated between them or against LGD-4033. Those accounts never name the content of the material, which for the YK-11 for sale here is measured for each batch.
Which gives the most muscle with the fewest side effects?
The compound named for the most muscle mass, in descriptions beyond the trials, is usually LGD-4033 or RAD140, with ostarine placed as the milder of the three and credited with less, and the ordering by adverse effects does not simply invert that list: outside the published trials, ostarine is the gentler compound through the greater part of this material, while in at least one account RAD140 was credited with fewer adverse effects than ostarine.
In those accounts no agreed ranking emerges, so the lists of the best SARMs disagree with one another about which compound belongs at the top; the trade-off, more muscle mass against fewer adverse effects, is described rather than placed on a scale, and the three compounds are arranged along it differently from one account to the next.
Doses in the trials against exposure in the case reports
The doses behind the human data sit two orders of magnitude apart: RAD140 was administered at 50, 100 and 150 mg once daily to women with metastatic breast cancer, with 100 mg the maximum tolerated dose, and LGD-4033 at 0.1 to 1.0 mg daily to healthy men over three weeks, and neither schedule was designed to represent what circulates outside a trial.
The published cases record exposure rather than dose, drug-induced liver injury following 5 weeks, three months and 16 weeks of exposure to RAD-140 obtained from consumer products of unverified strength, so the case exposures cannot be read against the trial RAD 140 dose, because the strength behind them is unknown.
A trial dose therefore says nothing about the content of a product sold under the same name. A milligram figure on a label states a declared amount rather than a measured one, and the analytical checks below show how often the declared and the measured part company. For laboratory research the buy RAD 140 UK listing here carries batch and purity data for each lot.
Products labelled testolone, ligandrol or ostarine fail laboratory checks in both directions, too little of the declared compound or none of it, which is what separates legit RAD 140 from the rest.
The rest of the SARMs for sale UK here carry the same batch and purity data.
Return to baseline after LGD-4033
Once administration of LGD-4033 stopped, hormone levels and lipids both returned to baseline, the pre-treatment measurement, within the trial’s five-week follow-up, by day 56; the reversal covered the suppressed testosterone, SHBG, HDL cholesterol and triglyceride values alike, in the men who had received the sub-milligram and milligram doses.
For RAD140 the only recovery data concern liver tissue and are set out in the liver article; nothing comparable exists for its hormonal axis.
RAD140 in cell, rat and mouse studies
In gonadectomised male rats, their gonads surgically removed, RAD140 reduced hippocampal neuron loss in the kainate lesion model, which kills neurons with a systemic excitotoxin, and acted on peripheral tissues while largely sparing prostate tissue.
The cardiac work ran in older animals: mice of 23 months given 5 mg/kg daily for six weeks had an ejection fraction, the share of ventricular volume expelled per beat, 10.4% higher and a stroke volume 9.6 µL higher than controls, with better myocardial strain markers in males than in females. In the cell bioassays androgenic activity was lower in the yeast androgen screen than in the reporter gene assay in prostate carcinoma cells, a difference that bears on whether urinary screens of that kind detect such compounds at all; in cultured rat hippocampal neurons, the cellular side of RAD-140 neuroprotection, the compound matched testosterone against apoptotic insults through MAPK signalling.
What this comparison cannot settle
No trial has set any of these compounds against another, so this RAD 140 vs LGD comparison can rank none of them. The only human RAD140 trial enrolled 22 heavily pretreated women with metastatic breast cancer at doses far above those of the LGD-4033 trial, which in turn ran three weeks in small groups and was sponsored by the compound’s developer; single cases carry the rest of the human record, in one of them the authors call any causal role for the compounds speculative, and even the exposures behind those cases are uncertain, because products sold under these names frequently did not contain what the label declared. One of those cases concerns RAD-140 and the heart.
Seven of the comparisons drawn in this article are known from description alone. No published study among this article’s sources has measured any of them:
None of these SARMs has clinical approval, all are prohibited in sport at all times, and doping-control methods cover each of them.
Check what you remember
4 questions on this article; the right answer is marked.
MK-677 prompts the release of growth hormone and acts through the IGF-1 pathway, so it is not a SARM despite being sold under that label.
RAD140 entered human testing as vosilasarm in 22 heavily pretreated women with ER+/HER2- metastatic breast cancer, so its trial figures do not describe healthy people.
Raised AST was recorded in 59.1% of participants, ahead of raised ALT and bilirubin, while the LGD-4033 trial left both liver enzymes unchanged.
A SARM was confirmed in 9 of the 16 products, while in 7 the declared testolone, ostarine or andarine was not reliably identified.
Laura Walker, PhD · Newcastle University
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
RAD140 vs testosterone: strength, suppression and TRT
RAD140 vs testosterone compared on potency, prostate sparing and suppression, from binding assays, rat studies and the one human trial in breast cancer.
Is RAD 140 a steroid? How it differs from Anavar and tren
Is RAD 140 a steroid: no, it is a nonsteroidal SARM that activates the androgen receptor without the four-ring skeleton of Anavar or trenbolone.
Ostarine with cardarine: what is known and how they differ
The ostarine cardarine stack has one human record, a case of liver injury with rhabdomyolysis, and pairs a SARM with a PPAR-delta agonist.
Ostarine vs LGD: trial data, RAD140, MK-677 and anavar
Ostarine vs LGD has never been tested in one trial: separate placebo trials each recorded over 1 kg more lean mass, with lower testosterone and HDL.